1. Home
  2. FATE
  3. FATE Forecast

as of 12-05-2025 4:00pm EST

$1.08
$0.02
-1.82%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Frequently Asked Questions

Learn more about our FATE ML prediction model

What parameters are used to train the FATE ML model?

Our stocks FATE ML model is trained using historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other technical metrics.

How often is the FATE ML model updated?

We update our ML model weekly or biweekly (depending on market capitalization) using TensorFlow, typically over the weekend to ensure the most current predictions.

Why might the model accuracy vary?

Our current data provider offers limited historical data, which can impact accuracy. As we continue to gather more data and add additional indicators, we expect the model's accuracy to improve over time.

How can I contribute data to improve accuracy?

We greatly appreciate contributions! Please contact us at info@finquota.com to discuss how you can help improve our models.

Are shorter timeframe predictions available?

Yes, we offer predictions for strategy purposes with shorter intervals including 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes timeframes.

Should I use this for financial decisions?

Our ML model is designed for educational purposes only and should not be used as the sole basis for financial decisions. Always consult with a qualified financial advisor before making any investment decisions.

Share on Social Networks: